Clinical Trials Browser

Phase 1 × Interventional × palbociclib × Clear all

NCT03132454 2026-04-15

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT02159755 2026-04-13

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Mantle-Cell

NCT06997029 2026-04-07

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Phase 1 Recruiting

Neoplasms

NCT04360941 2026-04-06

PAveMenT

Phase 1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06654297 2026-04-02

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

Phase 1 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Phase 1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT04288089 2026-02-27

A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

Phase 1 Active not recruiting

31 enrolled 12 charts

Breast Neoplasms

NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Phase 1 Suspended

GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

NCT03332797 2026-02-13

A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT03170206 2026-02-12

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Phase 1 Completed

Lung Neoplasms

NCT02499146 2026-02-11

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Phase 1 Completed

26 enrolled 40 charts

Advanced Breast Cancer

NCT03616587 2026-01-28

SERENA-1

Phase 1 Active not recruiting

Breast Neoplasms

NCT03065387 2026-01-12

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase 1 Active not recruiting

Neoplasm Metastasis

NCT03685331 2026-01-09

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT05266105 2025-11-24

A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Phase 1 Active not recruiting

Breast Neoplasms

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Phase 1 Active not recruiting

Breast Neoplasms

NCT05216432 2025-09-22

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Phase 1 Recruiting

Breast Neoplasms

NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Phase 1 Recruiting

DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT06113809 2025-06-03

Palbociclib and Pembrolizumab in Sarcoma

Phase 1 Recruiting

Sarcoma

NCT05759949 2025-05-16

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Phase 1 Completed

Breast Neoplasms

NCT03472573 2025-05-15

Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Phase 1 Completed

Burkitt Lymphoma

NCT06941142 2025-04-23

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Phase 1 Not yet recruiting

Advanced Breast Cancer

NCT03498378 2025-04-03

Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT03792256 2025-03-21

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Phase 1 Completed

12 enrolled 24 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Recurrence, Leukemia, T-Cell, Lymphoma, T-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT05178888 2025-02-11

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT04996160 2025-01-24

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04818632 2024-12-17

AZD9833

Phase 1 Completed

Breast Neoplasms

NCT05293964 2024-11-29

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT03238196 2024-11-14

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Phase 1 Completed

35 enrolled 19 charts

Breast Neoplasms

NCT04060862 2024-11-08

IPATunity150

Phase 1 Terminated

20 enrolled 11 charts

Breast Neoplasms

NCT03900884 2024-11-07

PALVEN

Phase 1 Active not recruiting

Breast Neoplasm Female

NCT02389842 2024-09-26

PIPA

Phase 1 Completed

Breast Neoplasms

NCT02599714 2024-06-06

PASTOR

Phase 1 Completed

Breast Neoplasms

NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Phase 1 Completed

Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

NCT06307249 2024-03-12

PTST_PALBEVA

Phase 1 Recruiting

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03471663 2024-01-08

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT04483505 2023-12-28

ROGABREAST

Phase 1 Completed

BreastOther neoplasm

Breast Cancer Metastatic

NCT02897375 2023-10-10

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Phase 1 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT06065592 2023-10-06

CAT_PB

Phase 1 Unknown

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Cardiovascular Diseases, Colonic Neoplasms, Carcinoma, Hepatocellular, Immune System Diseases, Inflammation, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Thromboembolism, Thrombosis

NCT04872608 2023-04-28

A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT03455270 2022-12-15

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Phase 1 Completed

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT03128619 2022-09-26

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT02684032 2022-07-27

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies